- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 9 - The Role of Insurance and Medicare
Dr Chernew asks panelists about the role of insurers and Medicare for patients in the treatment of multiple myeloma. While insurers may not have necessarily been a barrier to care, costs of drugs have been.
Dr Chernew asks panelists about the role of insurers and Medicare for patients in the treatment of multiple myeloma. While insurers may not have necessarily been a barrier to care, costs of drugs have been.
Dr Reeder says that the insurance market shares the same concerns of the provider community, especially with regards to balancing the clinical and fiscal implications of patients’ treatment. The payer community is trying to better understand the evidence behind treatment options, and which patients would benefit most from certain treatments. He suggests that this kind of determination might be possible by knowing specific biomarkers. Insurers are seeking to see the link between effectiveness and cost.
Ms Young says that studies such as the CoMMpass study can assist insurers and providers alike in identifying which patients would benefit most from specific expensive agents.
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
